1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-212-573-2222

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300

Contact E-Mail: pfizer-MSDS@pfizer.com

Material Name: Methylprednisolone Sodium Succinate for Injection, USP

Trade Name: Solu-Medrol
Chemical Family: Mixture
Intended Use: Pharmaceutical product used as anti-inflammatory

2. HAZARDS IDENTIFICATION

Appearance: White powder
Signal Word: DANGER

Statement of Hazard: May damage the unborn child.
May cause damage to: blood and blood forming organs through prolonged or repeated exposure.

Additional Hazard Information:
Short Term: May cause eye irritation (based on components) . May be harmful if absorbed through the skin.
Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on blood and blood forming organs.

Known Clinical Effects: Adverse clinical reactions include the development of hypersensitivity and/or irritation leading to rashes, itching, and burning. Clinical use has resulted in hormonal alterations. Drugs of this class may cause Cushing's syndrome, manifested by moon face, obesity, headache, acne, thirst, increased urination, impotence, menstrual irregularities, facial hair growth, and mental changes.

EU Indication of danger: Toxic to reproduction: Category 1
Harmful

EU Hazard Symbols: T

EU Risk Phrases: R61 - May cause harm to the unborn child.
R48/22 - Harmful: danger of serious damage to health by prolonged exposure if swallowed.

2. HAZARDS IDENTIFICATION

Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benzyl Alcohol</td>
<td>100-51-6</td>
<td>202-859-9</td>
<td>Xn,R20/22</td>
<td>*</td>
</tr>
<tr>
<td>Methylprednisolone Sodium Succinate</td>
<td>2375-03-3</td>
<td>219-156-8</td>
<td>Repr.Cat.1;R61 Xn,R48/22</td>
<td>67-87</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lactose</td>
<td>63-42-3</td>
<td>200-559-2</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Sodium phosphate, monobasic</td>
<td>7558-80-7</td>
<td>231-449-2</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Sodium phosphate, dibasic</td>
<td>7558-79-4</td>
<td>231-448-7</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information: * Proprietary Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

For the full text of the R phrases mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.
## 6. ACCIDENTAL RELEASE MEASURES

### Health and Safety Precautions:
Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

### Measures for Cleaning / Collecting:
Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

### Measures for Environmental Protections:
Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

### Additional Consideration for Large Spills:
Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

## 7. HANDLING AND STORAGE

### General Handling:
Minimize dust generation and accumulation. Avoid contact with eyes, skin and clothing. Avoid breathing dust. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

### Storage Conditions:
Store as directed by product packaging.

## 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

### Benzyl Alcohol
- **Bulgaria OEL - TWA**
- **Czech Republic OEL - TWA**
- **Latvia OEL - TWA**
- **Lithuania OEL - TWA**
- **Poland OEL - TWA**

### Methylprednisolone Sodium Succinate
- **Pfizer OEL TWA-8 Hr:** 4 µg/m³, Skin

### Engineering Controls:
Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

### Environmental Exposure Controls:
Refer to specific Member State legislation for requirements under Community environmental legislation.

### Personal Protective Equipment:
Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

- **Hands:** Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.
- **Eyes:** Wear safety glasses or goggles if eye contact is possible.
- **Skin:** Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Molecular Formula: Mixture
Color: White
Molecular Weight: Mixture
Solvent Solubility: Soluble: Alcohols
Solubility: Soluble: Water

10. STABILITY AND REACTIVITY

Stability: Stable under normal conditions of use.
Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of various forms of the active ingredients. The remaining information describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

**Sodium phosphate, dibasic**
- Rat Oral LD 50 17 g/kg

**Sodium phosphate, monobasic**
- Rat Oral LD 50 8290 mg/kg

**Lactose**
- Rat Oral LD50 > 10 g/kg

**Benzyl Alcohol**
- Rat Oral LD50 1230 mg/kg
- Rat Intravenous LD50 53 mg/kg
- Rat Inhalation LC50 46 mg/m³

**Methylprednisolone Sodium Succinate**
- Rat Oral LD 50 > 5000 mg/kg
- Rat Intravenous LD 50 718 mg/kg
- Mouse Intravenous LD 50 953 mg/kg
- Rat Intraperitoneal LD 50 512 mg/kg
- Mouse Intraperitoneal LD 50 902 mg/kg

**Methylprednisolone**
- Rat Oral LD 50 > 2000 mg/kg
11. Toxicological Information

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

- Sodium phosphate, dibasic
  - Eye Irritation: Rabbit, Mild
  - Skin Irritation: Rabbit, Mild

- Benzyl Alcohol
  - Eye Irritation: Rabbit, Severe
  - Skin Irritation: Rabbit, Moderate
  - Skin Irritation: Guinea Pig, Moderate

- Methylprednisolone
  - Skin Irritation: Rabbit, No effect
  - Eye Irritation: Rabbit, No effect
  - Skin Sensitization - GPMT: Guinea Pig, No effect

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

- Methylprednisolone
  - 42 Day(s) Dog Oral 167 µg/kg/day LOAEL Adrenal gland
  - 6 Week(s) Rat Subcutaneous 500 µg/kg/day LOAEL None identified
  - 14 Week(s) Rat Subcutaneous 0.4 µg/kg/day NOAEL Blood forming organs Adrenal gland
  - 52 Week(s) Rat Subcutaneous 4 µg/kg/day NOAEL Blood forming organs Adrenal gland

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

- Methylprednisolone Sodium Succinate
  - Reproductive & Fertility: Rat Subcutaneous 40 mg/kg/day LOAEL Fetotoxicity
    - Embryo / Fetal Development: Rat Subcutaneous 40 mg/kg/day LOAEL Teratogenic

- Methylprednisolone
  - Reproductive & Fertility: Rat Subcutaneous 0.004 mg/kg/day NOAEL Paternal toxicity
  - Reproductive & Fertility: Rat Subcutaneous 0.02 mg/kg/day LOAEL Fetotoxicity
    - Embryo / Fetal Development: Rat Subcutaneous 1.0 mg/kg/day LOAEL Fetotoxicity, Teratogenic
    - Embryo / Fetal Development: Mouse Intramuscular 330 mg/kg/day LOAEL Teratogenic
    - Embryo / Fetal Development: Rabbit Intramuscular 0.1 mg/kg/day LOAEL Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

- Methylprednisolone Sodium Succinate
  - Direct DNA Interaction: Not applicable Negative
  - In Vitro Cytogenetics: Not applicable Negative

- Methylprednisolone
  - Bacterial Mutagenicity (Ames): Salmonella Negative
11. TOXICOLOGICAL INFORMATION

Unscheduled DNA Synthesis  Rat Hepatocyte  Negative
Mammalian Cell Mutagenicity  Chinese Hamster Ovary (CHO) cells  Negative
Direct DNA Interaction  Negative

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be avoided.

13. DISPOSAL CONSIDERATIONS

Disposal Procedures: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Symbol: T
EU Indication of danger: Toxic to reproduction: Category 1
Harmful
EU Risk Phrases: R61 - May cause harm to the unborn child.
R48/22 - Harmful: danger of serious damage to health by prolonged exposure if swallowed.
EU Safety Phrases: S22 - Do not breathe dust.
S36/37 - Wear suitable protective clothing and gloves.
S53 - Avoid exposure - obtain special instructions before use.

OSHA Label: DANGER
May damage the unborn child.
May cause damage to: blood and blood forming organs through prolonged or repeated exposure.
15. REGULATORY INFORMATION

Canada - WHMIS: Classifications
WHMIS hazard class:
Class D, Division 2, Subdivision A

16. OTHER INFORMATION

Text of R phrases mentioned in Section 3
R61 - May cause harm to the unborn child.
R20/22 - Harmful by inhalation and if swallowed.
R48/22 - Harmful: danger of serious damage to health by prolonged exposure if swallowed.

Data Sources: Publicly available toxicity information. Pfizer proprietary drug development information. Safety data sheets for individual ingredients.

Reasons for Revision: Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 4 - First Aid Measures. Updated Section 5 - Fire Fighting Measures. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 13 - Disposal Considerations.
Prepared by:  
Toxicology and Hazard Communication 
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet